Tag Archives: $39B

AstraZeneca’s $39B Alexion buyout scores EU blessing but still awaits key nod from the UK

AstraZeneca’s $ 39 billion takeover of rare disease specialist Alexion has another regulatory blessing in the bag, but the pair are still holding out for a key nod from the U.K. to settle the deal.  AstraZeneca on Tuesday said that the European Union has approved its acquisition of Boston-based Alexion, inching closer toward its goal… Read More »